Which peptides are most commonly combined with Oxymetholone in bodybuilding protocols?

GHRP-2, GHRP-6, and Ipamorelin are the most frequently reported co-administration choices, as each stimulates pituitary GH release via the GHSR-1a receptor — a pathway mechanistically separate from Oxymetholone's androgen receptor activity. CJC-1295 (with or without DAC) is commonly added as a GHRH analogue to amplify GH pulse amplitude. This combination engages two independent anabolic axes without receptor-level competition.

How should I time Oxymetholone doses within a GHRP or GHRH peptide cycle?

Position Oxymetholone as a defined sub-window — typically weeks three through six or four through eight — nested within a longer peptide run of eight to twelve weeks, so serum IGF-1 has time to rise toward its plateau before the oral androgen is introduced. Peptide injections should be administered on an empty stomach to avoid blunting GH pulse amplitude; Oxymetholone timing within the same window is managed separately based on your training schedule.

Does combining Oxymetholone with peptides increase liver stress compared to using Oxymetholone alone?

Peptides themselves are not hepatotoxic — they are peptide chains cleared by systemic proteases, not 17α-alkylated compounds processed through hepatic CYP pathways. Liver enzyme elevation in a peptide-inclusive protocol is therefore attributable to the oral androgenic component, not the peptide. Monitoring ALT and AST at the midpoint and endpoint of the Oxymetholone sub-window isolates the oral compound's hepatic contribution with sufficient resolution.

Can I split NordiPolon 25mg tablets to adjust my dose when combining with peptides?

Splitting is mechanically possible but introduces API distribution uncertainty, since tablet homogeneity across the fractional surface cannot be guaranteed without individual half-tablet assay. The 25 mg unit is already the minimum practical dose increment for most practitioners; building your protocol around whole-tablet increments preserves the per-dose accuracy confirmed by NordiPolon's batch-level HPLC content-uniformity testing.

How does the 100-tablet pack size of NordiPolon fit a peptide-stack cycle without requiring a supplementary order?

At 25 mg per day, the 100-tablet pack covers exactly one hundred days — far exceeding any single Oxymetholone sub-window, so a practitioner running a four-week oral phase at 25 mg daily uses 28 tablets, leaving substantial reserve for a second phase or a dose escalation to 50 mg daily without an additional purchase mid-cycle. This surplus supports flexible protocol adjustment as serum IGF-1 response data come in from the concurrent peptide administration. (2) angle_used

Authenticity Verified

Nordi Pharma

NordiPolon 25mg/tab 100 Tabletten by Nordi Pharma

Name: NordiPolon 25mg/tab 100 Tablets by Nordi Pharma
Brand: Nordi Pharma
SKU: ORA-OXYM-NOR-016
Price: 60.00 EUR
Availability: InStock

NordiPolon is an oral anabolic androgenic steroid delivering Oxymetholone at 25 mg per tablet across a 100-tablet count, engineered for practitioners who pair DHT-derived oral androgens with growth-factor peptide protocols to maximise distinct but complementary anabolic pathways. The 25 mg unit dose provides granular titration flexibility when adjusting Oxymetholone exposure alongside peptide variables such as dosing frequency and IGF-1 response windows. Every production lot undergoes independent third-party HPLC content-uniformity verification and LAL endotoxin screening prior to release — traceability is documented at batch level, not inferred from bulk sampling alone.

€60.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Recruits androgen receptor and GH-receptor signalling simultaneously when co-administered with GHRPs — two independent anabolic axes in a single protocol.
25 mg tablet unit allows single-increment dose adjustments that align precisely with evolving IGF-1 response data from concurrent peptide administration.
100-tablet count provides complete supply for a defined oral sub-window inside a longer peptide run without requiring a mid-cycle supplementary purchase.
DHT-derived backbone confers resistance to aromatase conversion, keeping the oestrogenic variable isolated to any injectable partner rather than compounded by the oral component.
Third-party HPLC batch verification ensures each tablet delivers the declared 25 mg — critical for calculating the oral-to-peptide anabolic ratio accurately at protocol design.
Erythropoietic activity increases red-cell precursor output through androgen receptor-mediated mechanisms, complementing the lean-tissue partitioning effects of peptide-driven IGF-1 elevation.
Compact blister-pack format maintains tablet integrity and moisture control across the full 100-tablet count, preserving API stability through multi-week peptide protocols.

Phase	dosage	Note
Peptide Ramp (Weeks 1–4)	Peptides only; NordiPolon not yet introduced	Allow GHRP/GHRH administration to elevate baseline IGF-1 before adding the oral androgen; confirm rising IGF-1 trend by serum assay at week 4
Oral Induction within Peptide Cycle (Weeks 5–6)	25 mg Oxymetholone once daily	Introduce NordiPolon at the lower dose unit; assess ALT/AST at week 6 before escalating; continue peptide protocol unchanged
Peak Oral Phase within Peptide Cycle (Weeks 7–8)	50 mg Oxymetholone daily (two 25 mg tablets)	Biomarker checkpoint at week 6 gate-keeps this escalation; concurrent peptide dosing continues at the established frequency
Oral Taper and Peptide Continuation (Weeks 9–10)	25 mg Oxymetholone daily, then cessation	Step down to single tablet before stopping the oral; peptide protocol continues beyond the oral window to maintain IGF-1 elevation through PCT
Peptide Continuation / PCT (Weeks 11–12+)	Peptides only; NordiPolon discontinued	Draw final ALT/AST four weeks post-Oxymetholone cessation to isolate oral androgenic hepatic contribution from ongoing peptide-related metabolic shifts

Key takeaways

Pair NordiPolon with GHRPs to engage two mechanistically distinct anabolic pathways simultaneously.
Nest the Oxymetholone window inside the longer peptide cycle after IGF-1 begins rising.
Monitor ALT and AST mid-cycle to isolate the oral androgenic hepatic signal from peptide effects.
Use whole 25mg tablets to preserve the per-dose accuracy confirmed by third-party HPLC assay.
Reserve the 100-tablet pack for flexible dose adjustment as peptide response data emerge.

Oxymetholone and Peptide Co-Administration: A Mechanistically Distinct Anabolic Framework

NordiPolon delivers Oxymetholone as a 25 mg oral tablet designed for integration into peptide-inclusive anabolic protocols, where androgen receptor-mediated transcription and peptide-driven growth-factor signalling operate through separate receptor systems to produce genuinely additive physiological output. Unlike combining two androgens — which risks pathway redundancy — pairing an oral androgenic compound with GH-releasing peptides (GHRPs) or GH-releasing hormone analogues (GHRHs) recruits mechanistically orthogonal signalling cascades. NordiPolon supports this architecture by allowing incremental dose adjustment at the 25 mg level, a precision benefit relevant when titrating against peptide-induced IGF-1 responses tracked by serum assay.

How Peptide Receptor Systems Complement Androgen Receptor Signalling

Growth hormone-releasing peptides such as GHRP-2 and GHRP-6 stimulate pituitary GH secretion via the ghrelin receptor (GHSR-1a), subsequently elevating hepatic and peripheral IGF-1 output — a pathway that operates entirely upstream of androgen receptor engagement. Oxymetholone drives nitrogen retention and red-cell precursor proliferation through AR-mediated gene transcription at the nuclear level. These two mechanisms do not compete for the same receptor occupancy, which means co-administration produces additive anabolic stimulus rather than simple dose-stacking of a single pathway. Compared to stacking two 17α-alkylated oral androgens — which converges on identical AR-mediated transcription — a GHRP/Oxymetholone combination expands the mechanistic surface area of the protocol without proportionally compounding hepatic alkylation burden.

Dosing Architecture for Peptide-Stacked Protocols

Peptide co-administration typically extends a practitioner's overall cycle duration beyond the short windows used for oral-only androgens, because GHRPs and GHRH analogues require eight to twelve weeks of continuous use for serum IGF-1 to reach a meaningful response plateau, as confirmed by serial IGF-1 immunoassay. Oxymetholone is therefore positioned within a defined sub-window of the longer peptide cycle rather than run concurrently for its full duration. The 100-tablet pack at 25 mg supports a structured four-week Oxymetholone phase nested inside a longer peptide protocol without exceeding evidence-informed hepatic exposure limits. ALT and AST panels should be drawn at the midpoint and conclusion of the oral androgenic window to isolate its hepatic contribution from peptide-associated metabolic shifts on the same panel.

Quality and Analytical Traceability

Nordi Pharma submits each NordiPolon batch to independent third-party laboratory analysis: HPLC potency assay confirms that each tablet contains Oxymetholone within specification at 25 mg, and LAL endotoxin screening clears the API before compression. Batch-level documentation links every pack to its analytical release record, supporting accurate pharmacological planning in multi-compound protocols where per-tablet dose accuracy directly affects the calculated oral-to-peptide anabolic ratio.

Usage

Establish your peptide protocol first: select GHRP (e.g., GHRP-2 or Ipamorelin) and a GHRH analogue, set injection frequency, and run for at least four weeks before introducing NordiPolon so that a rising IGF-1 baseline is confirmed by serum assay.
Draw a pre-Oxymetholone baseline blood panel including ALT, AST, haematocrit, and fasting glucose — this panel anchors all subsequent monitoring comparisons and allows the oral androgenic contribution to be separated from peptide-related metabolic shifts.
Introduce NordiPolon at one 25 mg tablet daily during week five of the peptide cycle; swallow whole with water at a consistent daily time — avoid high-fat meals immediately before dosing to support predictable gastrointestinal transit.
At the week-six biomarker checkpoint, review ALT and AST results: if both remain below twice the upper reference limit, advance to two tablets (50 mg/day); if either is elevated, hold at 25 mg/day and reassess at week seven.
Continue the peptide injection schedule unchanged throughout the Oxymetholone sub-window — peptide GH-pulse timing operates independently of oral androgen timing, so no scheduling conflict arises between the two protocols.
Taper NordiPolon back to 25 mg/day for the final week of the oral phase before stopping completely; continue the peptide protocol beyond Oxymetholone cessation, and draw a closing liver panel four weeks after the last NordiPolon tablet to isolate hepatic recovery from concurrent peptide-driven metabolic activity.

Warnings

contraindications: NordiPolon is contraindicated in individuals with active hepatic disease, significantly elevated baseline liver enzymes, prostate or breast carcinoma, pregnancy, or hypersensitivity to Oxymetholone or any tablet excipient. Do not introduce the oral androgenic phase of any peptide stack until a pre-cycle panel confirms liver enzyme values within the reference range.

side_effects: Hepatotoxicity is the primary risk associated with 17α-alkylated oral androgens; elevation of ALT and AST is expected and should be tracked at defined intervals. Additional effects include fluid retention, alterations in HDL/LDL cholesterol ratio, potential blood pressure elevation secondary to increased red-cell mass, and acne. Progestogenic receptor cross-reactivity may contribute to gynecomastia risk independent of aromatisation.

monitoring: Obtain ALT, AST, haematocrit, lipid panel, and fasting glucose at baseline, at the midpoint of the Oxymetholone sub-window, and four weeks post-cessation. The four-week post-cessation draw is particularly important in peptide-inclusive protocols because GH-related effects on glucose metabolism remain active and must be distinguished from residual oral androgenic hepatic signals on the same panel. Haematocrit values approaching or exceeding 54% warrant immediate dose review.

pct: Post-cycle therapy targeting HPG-axis recovery remains necessary following Oxymetholone administration. Standard SERM-based protocols (Tamoxifen or Clomiphene) apply. Because the peptide protocol typically continues through and beyond PCT, liver enzyme recovery can be tracked alongside ongoing IGF-1 monitoring — use separate reference ranges for each biomarker category rather than conflating them.

Frequently asked questions

Which peptides are most commonly combined with Oxymetholone in bodybuilding protocols?: GHRP-2, GHRP-6, and Ipamorelin are the most frequently reported co-administration choices, as each stimulates pituitary GH release via the GHSR-1a receptor — a pathway mechanistically separate from Oxymetholone's androgen receptor activity. CJC-1295 (with or without DAC) is commonly added as a GHRH analogue to amplify GH pulse amplitude. This combination engages two independent anabolic axes without receptor-level competition.
How should I time Oxymetholone doses within a GHRP or GHRH peptide cycle?: Position Oxymetholone as a defined sub-window — typically weeks three through six or four through eight — nested within a longer peptide run of eight to twelve weeks, so serum IGF-1 has time to rise toward its plateau before the oral androgen is introduced. Peptide injections should be administered on an empty stomach to avoid blunting GH pulse amplitude; Oxymetholone timing within the same window is managed separately based on your training schedule.
Does combining Oxymetholone with peptides increase liver stress compared to using Oxymetholone alone?: Peptides themselves are not hepatotoxic — they are peptide chains cleared by systemic proteases, not 17α-alkylated compounds processed through hepatic CYP pathways. Liver enzyme elevation in a peptide-inclusive protocol is therefore attributable to the oral androgenic component, not the peptide. Monitoring ALT and AST at the midpoint and endpoint of the Oxymetholone sub-window isolates the oral compound's hepatic contribution with sufficient resolution.
Can I split NordiPolon 25mg tablets to adjust my dose when combining with peptides?: Splitting is mechanically possible but introduces API distribution uncertainty, since tablet homogeneity across the fractional surface cannot be guaranteed without individual half-tablet assay. The 25 mg unit is already the minimum practical dose increment for most practitioners; building your protocol around whole-tablet increments preserves the per-dose accuracy confirmed by NordiPolon's batch-level HPLC content-uniformity testing.
How does the 100-tablet pack size of NordiPolon fit a peptide-stack cycle without requiring a supplementary order?: At 25 mg per day, the 100-tablet pack covers exactly one hundred days — far exceeding any single Oxymetholone sub-window, so a practitioner running a four-week oral phase at 25 mg daily uses 28 tablets, leaving substantial reserve for a second phase or a dose escalation to 50 mg daily without an additional purchase mid-cycle. This surplus supports flexible protocol adjustment as serum IGF-1 response data come in from the concurrent peptide administration. (2) angle_used

Manufacturer

Independent third-party laboratory engagement sits at the operational centre of Nordi Pharma's release process for NordiPolon: rather than relying on in-house quality infrastructure alone, Nordi Pharma routes each production batch to external analytical partners whose HPLC instrumentation is calibrated and maintained independently of Nordi Pharma's own laboratory environment. The resulting content-assay report — confirming that each NordiPolon tablet falls within specification at 25 mg Oxymetholone — is generated by a facility with no commercial dependency on the outcome, which removes the conflict-of-interest inherent in self-certified release testing. LAL endotoxin screening of the API prior to tablet compression is conducted under the same externally verified framework. Each completed batch carries documentation that cross-references the analytical release records from these third-party partners, giving practitioners who incorporate NordiPolon into multi-compound peptide protocols an independently verified per-tablet potency figure rather than a manufacturer-declared estimate.

Product details

Brand	Nordi Pharma
Active ingredient	oxymetholone
Also known as	Anadrol, Anapolon, Oxymetholone, NordiPolon, Nordi Pharma Anadrol
Strength	25 mg
Form	Tabletten
Pack size	100 pieces
Item number	ORA-OXYM-NOR-016

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Anapolon 50mg/tab 20 Tablets by Abdi Ibrahim

Lab Tested

Anapolon 50mg/tab 20 Tabletten by Abdi Ibrahim

Anapolon (Oxymetholone) by Abdi Ibrahim is a 17α-alkylated dihydrotestosterone-derived oral anabolic steroid, dosed at 50 mg per tablet across 20 tablets, whose primary pharmacological identity is defined by its high-affinity interaction with androgen receptors combined with a marked capacity to stimulate erythropoietin production. As a DHT-lineage compound, Oxymetholone cannot be aromatised directly yet drives powerful anabolic signalling through androgen receptor activation and progesterone receptor cross-reactivity. Quality is enforced at every production stage: HPLC purity verification, LAL endotoxin testing, and GMP-certified manufacturing conditions underpin every blister pack released by Abdi Ibrahim.

€20.00

Anapolon 50mg/tab 60 Tablets by Balkan Pharmaceuticals

HPLC Verified

Anapolon 50mg/tab 60 Tabletten by Balkan Pharmaceuticals

Anapolon by Balkan Pharmaceuticals is an oral anabolic tablet delivering 50 mg of Oxymetholone per dose, clinically characterised by a plasma half-life of approximately 8–9 hours that governs its twice-daily administration schedule. The pharmacokinetic profile allows predictable plasma-level maintenance without the accumulation spikes associated with longer-half-life oral androgens, making timed dosing a core performance variable. Batch-release integrity is enforced through post-compression HPLC quantification and LAL endotoxin screening — each of the 60 tablets verified against declared potency before dispatch.

€48.00

Pro-Anadrol 50mg/tab 50 Tablets by Beligas Pharmaceuticals

Pharma Grade

Pro-Anadrol 50mg/tab 50 Tabletten by Beligas Pharmaceuticals

Pro-Anadrol delivers Oxymetholone at 50 mg per tablet across a 50-tablet pack — an oral androgen whose systemic bioavailability is shaped entirely by first-pass hepatic metabolism, distinguishing its absorption profile sharply from any injectable androgenic compound. Because the molecule must survive gastrointestinal transit and initial liver processing before entering systemic circulation, oral Oxymetholone achieves estimated bioavailability in the 56–70 % range, a figure that injectable routes bypass entirely by delivering the active substance directly into the bloodstream. Batch-level potency is confirmed at Beligas Pharmaceuticals through HPLC quantification against certified pharmacopoeial reference standards, with LAL endotoxin screening applied to raw excipient inputs before tableting proceeds.

€60.00

OxyTrex 25mg/tab 100 Tablets by Concentrex Labs

Purity Tested

OxyTrex 25mg/tab 100 Tabletten by Concentrex Labs

OxyTrex by Concentrex Labs delivers Oxymetholone at 25 mg per tablet across 100 tablets, formulated specifically for athletes studying how this potent oral androgen interacts with insulin sensitivity and glucose partitioning during hypertrophic loading phases. Oxymetholone's documented capacity to alter nutrient uptake dynamics — shifting glucose disposal toward skeletal muscle — makes it a subject of sustained interest in metabolic-context bodybuilding literature. Purity Tested at the finished-tablet stage via HPLC quantification; each released lot carries a batch record confirming active-content compliance against a certified reference standard.

€60.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00